What Is 5-Amino-1MQ?
5-Amino-1MQ is an experimental small molecule studied for its ability to inhibit nicotinamide N-methyltransferase, usually shortened to NNMT. NNMT is an enzyme, meaning a protein that speeds up a chemical reaction in the body. It transfers a methyl group to nicotinamide, a form of vitamin B3 involved in cellular metabolism.
Despite appearing in peptide catalogues, 5-Amino-1MQ is not a peptide. Peptides are chains of amino acids. 5-Amino-1MQ is a quinolinium compound with a much smaller, non-peptide chemical structure. Orentra includes it as an adjacent compound because it is often marketed beside research peptides, not because it belongs to the same molecular class.
What does the name mean?
The longer chemical name is 5-amino-1-methylquinolinium. “Quinolinium” describes the positively charged ring system at the centre of the molecule. “1-methyl” identifies a methyl group attached to one position, while “5-amino” identifies an amino group attached to another.
The abbreviation 5A1MQ is used in research papers and commercial descriptions. It should not be confused with an amino-acid sequence. The word amino in a chemical name does not make a substance a peptide. An amino group is a chemical feature that can occur in many molecules.
What is NNMT?
Nicotinamide N-methyltransferase is present in several human tissues, including liver and fat tissue. It uses a methyl donor called S-adenosylmethionine, shortened to SAM, to convert nicotinamide into 1-methylnicotinamide.
A methyl group is a small arrangement of one carbon and three hydrogen atoms. Cells add methyl groups to many molecules as part of normal metabolism and regulation. SAM supplies these groups, and the transfer leaves a product called S-adenosylhomocysteine. These reactions connect NNMT to nicotinamide use, methyl availability and the wider network that maintains nicotinamide adenine dinucleotide, or NAD+.
NAD+ is a coenzyme, which means it helps enzymes carry out reactions. It is involved in energy metabolism, DNA repair and cellular signalling. Blocking NNMT might change how nicotinamide and methyl donors are used. That mechanism is more complicated than saying the compound “raises NAD+” or “boosts metabolism”. A pathway change does not tell us whether a person will lose weight or become healthier.
When was 5-Amino-1MQ first documented?
NNMT itself has been studied for much longer, but 5-Amino-1MQ emerged from medicinal-chemistry work published in 2017. Medicinal chemistry is the design and testing of molecules that might modify a biological target.
The researchers screened chemical structures for compounds that inhibited NNMT, then examined potency and selectivity. Potency describes the concentration needed to produce an experimental effect. Selectivity asks whether a compound acts more strongly on the intended target than on other proteins.
The 2017 work identified 5-Amino-1MQ as a cell-active NNMT inhibitor. A 2018 paper then reported metabolic findings in mice with diet-induced obesity. Later animal studies explored related questions, including fat-cell biology and metabolic disease models.
| Year | Development |
|---|---|
| Before 2017 | NNMT was investigated in metabolism, cancer biology and methyl-group regulation |
| 2017 | 5-Amino-1MQ was reported as a cell-active small-molecule NNMT inhibitor |
| 2018 | A mouse study reported lower fat mass and changes in metabolic measurements after NNMT inhibition |
| 2022 onwards | Additional cell and animal papers examined metabolic and tissue effects |
| September 2026 | No established controlled human treatment evidence was identified |
What is 5-Amino-1MQ made from?
5-Amino-1MQ is made by chemical synthesis from smaller organic starting materials. It is not extracted from a gland, made by linking amino acids, or copied from a natural human peptide.
Published chemistry describes building the quinoline ring system and introducing the required amino and methyl groups through controlled reactions. A final methylation step creates the charged 1-methylquinolinium structure. Depending on the route, the product may be isolated with a negatively charged counter-ion to form a stable salt.
Raw materials in this type of synthesis include substituted aromatic compounds, solvents, acids, bases and methylating reagents. These are processing materials, not nutritional ingredients. The crude reaction mixture must be purified to remove unreacted starting substances, alternative structures and reaction by-products.
Analytical methods such as liquid chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry can be used to check purity and identity. Nuclear magnetic resonance examines the chemical environments of atoms in a molecule. Mass spectrometry measures mass and fragmentation patterns. Neither test alone establishes that a product is suitable for human use.
Why are researchers interested in NNMT inhibition?
Researchers have found higher NNMT expression in some forms of fat tissue and in several diseases. Expression means how much of the enzyme a cell makes. Inhibiting NNMT could alter the balance of nicotinamide, NAD+-related metabolism and methyl donors.
In fat cells, those changes might affect how energy is stored or released. In tumours, NNMT can be associated with altered metabolism and the surrounding tissue environment. In fibrotic disease, where excessive scar-like material accumulates in an organ, methyl metabolism may influence cell behaviour.
These are separate research areas. Evidence that NNMT is associated with one disease does not show that 5-Amino-1MQ treats it. An enzyme can have useful functions in normal tissues and harmful associations in a disease model. Blocking it throughout the body could therefore have effects that are difficult to predict.
What did the original laboratory research show?
The 2017 study tested 5-Amino-1MQ in biochemical assays and cultured cells. A biochemical assay measures a reaction using isolated components. A cell assay asks whether the compound enters or affects living cells under laboratory conditions.
Researchers reported inhibition of NNMT and changes in nicotinamide methylation. These findings established target engagement, meaning evidence that the compound interacted with the intended enzyme in the experimental system.
Target engagement is an early research milestone. It is not a health outcome. A substance can block an enzyme in a dish yet fail because it is poorly absorbed, breaks down rapidly, reaches the wrong tissues or causes harmful effects.
What have mouse obesity studies found?
The best-known 2018 study used mice with obesity caused by a high-fat diet. This is called a diet-induced obesity model. The mice received 5-Amino-1MQ by intraperitoneal injection, meaning injection into the abdominal cavity, a common laboratory route that is not the same as ordinary human treatment.
The researchers reported reduced fat mass without a corresponding loss of lean mass. They also reported changes in fat-cell size, energy expenditure and metabolic measurements. The model was designed to test a biological hypothesis, not to establish a human weight-loss medicine.
Several limitations matter:
- mice process drugs and energy differently from people;
- the route and controlled laboratory exposure do not reflect an unregulated commercial product;
- body-composition changes in a short animal experiment do not establish long-term health benefit;
- the study was not designed to detect uncommon or delayed harms in humans;
- a result in diet-induced obesity does not show that the compound treats every cause of weight gain.
Later studies have continued to investigate NNMT inhibition in animals. The direction of the findings does not change the evidence category. They remain preclinical, meaning completed before adequate human clinical testing.
Study design, not dosing guidance
Animal papers report administration in milligrams per kilogram of animal body weight. Those levels describe experiments in specific mouse or rat models. Converting an animal exposure into a personal amount is not valid simply by multiplying or dividing by body weight. Species, route, absorption, metabolism, formulation and safety margins all matter.
Orentra does not reproduce a step-by-step exposure calculation because 5-Amino-1MQ has no established human treatment programme. The useful context is that the published work used controlled laboratory material, defined animal models and monitored outcomes. It did not establish a human dose.
Has 5-Amino-1MQ been tested in people?
No published controlled human treatment trials were identified for this review. This means there is no dependable evidence for clinical weight loss, body composition, blood-sugar control, exercise performance, ageing or any other claimed benefit.
It also means basic clinical questions remain unanswered. Researchers have not established oral bioavailability in people, which is the proportion of a swallowed amount that reaches the bloodstream. They have not established the human half-life, meaning the time for the circulating amount to fall by half. There is no validated therapeutic range and no adequate human adverse-event dataset.
An online account of personal use is not a clinical trial. It usually lacks identity testing, a comparison group, blinding and systematic safety follow-up. Blinding means that participants, researchers or both do not know which intervention was received, reducing the risk that expectations influence reporting.
Is 5-Amino-1MQ a fat burner?
“Fat burner” is a marketing phrase, not a defined medical mechanism. The mouse literature gives researchers a reason to study NNMT and energy balance, but it does not show that 5-Amino-1MQ safely reduces human body fat.
Human weight change is influenced by appetite, food intake, physical activity, sleep, medicines, illness, hormones and the environment. A compound that changes a metabolic pathway in mice cannot be assumed to overcome those factors in people.
Weight alone is also not enough. A useful obesity medicine must show an acceptable balance of benefits and harms, ideally with evidence for metabolic health, cardiovascular outcomes, treatment persistence and what happens after treatment stops.
Does 5-Amino-1MQ increase NAD+?
Some experimental work links NNMT inhibition with changes in nicotinamide and NAD+-related metabolism. This has led to claims that 5-Amino-1MQ “saves” nicotinamide for NAD+ production.
The pathway is real, but the clinical conclusion is not established. NAD+ levels differ by tissue and are controlled by production, recycling and consumption. A change in one compartment or animal tissue does not show that a person experiences better energy, slower ageing or improved health.
NAD+ is also not a simple fuel gauge. It participates in redox reactions, where electrons are transferred, and acts as a substrate for signalling enzymes. More is not automatically better in every tissue or disease.
What about cancer research?
NNMT is expressed at higher levels in some tumours and in cells around tumours. Researchers are examining whether the enzyme helps cancer cells alter metabolism, methylation or the tissue environment.
This does not make 5-Amino-1MQ a cancer treatment. Cancer findings may involve isolated cells or mouse models, and the relevance can vary greatly between tumour types. A compound intended for cancer treatment would require extensive toxicology, manufacturing controls and phased clinical trials.
It is equally inappropriate to infer that NNMT inhibition is automatically safe because the target is being studied in cancer. Metabolic enzymes can have important functions in healthy cells.
What are the safety concerns?
The largest safety problem is the absence of an adequate human evidence base. A lack of reported harm is not evidence of safety when few or no people have been studied systematically.
Potential areas of uncertainty include:
- effects on methyl-group balance and pathways that use SAM;
- effects on nicotinamide handling and NAD+-related metabolism;
- off-target activity, meaning action on proteins other than NNMT;
- liver and kidney handling of the compound and its breakdown products;
- reproductive and developmental toxicity;
- immune, cardiovascular or neurological effects;
- interaction with medicines or underlying disease;
- identity, strength and contamination of products sold outside regulated medicine supply.
Short animal experiments cannot resolve all of these questions. A product described as “research grade” is not a clinical quality standard. It may be accompanied by a certificate showing one analytical result, but that does not establish batch consistency, stability, contaminants or suitability for consumption.
Is 5-Amino-1MQ approved?
5-Amino-1MQ is not an approved medicine for obesity, diabetes, metabolic disease, cancer, ageing or any other condition in the United States or United Kingdom.
The absence of approval is not just an administrative detail. It means regulators have not reviewed a finished 5-Amino-1MQ medicine and concluded that its benefits outweigh its risks for a defined use. There is no approved prescribing information that sets out indications, contraindications, manufacturing standards or adverse reactions.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Reduces body fat | Positive findings in mouse obesity models; no established human effect |
| Preserves muscle while losing fat | A body-composition finding in mice; no controlled human evidence |
| Speeds metabolism | Changes in experimental energy measurements; no validated human benefit |
| Raises NAD+ | Mechanistic and tissue-specific research; no proven clinical outcome |
| Reverses ageing | No evidence |
| Treats diabetes | No approved indication or established human treatment evidence |
| Treats cancer | Early target research only; not a cancer therapy |
How does the evidence compare with approved obesity medicines?
Approved obesity medicines have been studied in phased clinical programmes involving hundreds or thousands of people. Trials define the product, population, comparison group, duration, benefits and adverse events. Some programmes also examine cardiovascular outcomes.
5-Amino-1MQ has not crossed that threshold. It is not reasonable to compare a percentage change in mouse fat mass with human weight-loss results from semaglutide, tirzepatide or another approved medicine. The species, outcomes and evidence quality are different.
What research would be needed next?
Before claims of human benefit could be made, researchers would need:
- reproducible manufacture and impurity control;
- toxicology in more than one animal species where appropriate;
- pharmacokinetic studies showing how the compound is absorbed, distributed, broken down and removed;
- an initial Phase 1 trial focused mainly on safety and tolerability;
- controlled Phase 2 studies in a clearly defined condition;
- larger and longer trials able to measure meaningful clinical outcomes and less common harms.
A Phase 1 trial is normally the first stage in people and focuses mainly on safety and how the body handles a substance. Phase 2 asks whether there is a useful signal in people with the condition. Phase 3 compares the treatment in larger groups and provides much of the evidence used for approval decisions.
Why can NNMT be helpful in one tissue and harmful in another?
NNMT is part of normal metabolism. The liver uses it to process nicotinamide and other compounds. In fat tissue, its activity may influence energy and methyl-group balance. In some cancers, high NNMT expression is associated with altered tumour metabolism or the surrounding connective tissue.
The same enzyme can therefore have different roles by location and disease. Systemic inhibition means exposing multiple tissues, not selecting only the fat cells or tumour cells that a researcher is interested in.
This is a common challenge in drug development. A target can be biologically attractive but difficult to change without affecting normal functions. Human trials need to measure both the intended pathway and wider consequences.
What exactly did the mouse studies measure?
Animal metabolic studies may report body weight, fat mass, lean mass, food intake, energy expenditure, glucose handling and tissue gene expression. These outcomes are not interchangeable.
Energy expenditure can be estimated by indirect calorimetry, which measures oxygen use and carbon-dioxide production. Body composition may be estimated with imaging or chemical methods. Glucose tolerance tests examine how blood glucose changes after a glucose challenge.
An improvement in one measure does not establish overall health. For example, lower fat mass could occur with illness or reduced food intake. Researchers therefore compare food consumption, activity and lean tissue alongside weight.
Mouse housing temperature also affects metabolism. Standard laboratory rooms are cool for mice, causing them to produce more heat than humans living in a comfortable environment. This can change how metabolic interventions appear.
Why is selectivity important?
A molecule described as an NNMT inhibitor may interact with other enzymes, receptors or ion channels. Selectivity testing compares the intended target with a panel of alternatives. Early panels never cover every human protein.
The concentration used in an assay matters. At low concentration, a compound may mostly affect NNMT. At higher exposure, weaker off-target interactions can become important. Metabolites may also have different activities from the original molecule.
Human pharmacology would need to show target engagement at an exposure below levels that cause unacceptable off-target effects. Without that work, a label such as “selective NNMT inhibitor” remains an experimental description rather than a safety guarantee.
What is the relevance of the salt form?
5-Amino-1MQ is commonly described as an iodide salt. The positively charged 5-amino-1-methylquinolinium ion is paired with iodide, a negatively charged ion. Other salt forms could have different solubility, stability or mass.
This means that the mass of a salt includes the counter-ion as well as the active part. Product descriptions that switch between free compound and salt without explanation can create inaccurate comparisons.
Iodide in the chemical salt should not be confused with a nutritional iodine supplement. The intended research activity comes from the quinolinium component, and the product has not been established as a safe source of dietary iodine.
Why do online before-and-after reports add little evidence?
Weight changes over a short period can reflect water, glycogen, gut contents, fat or muscle. Glycogen is stored carbohydrate that holds water. Photographs are affected by lighting, posture and selection.
Self-reports also cannot separate the compound from changes in food intake, training, other products or expectation. Without a verified product and comparison group, they do not show causation.
Clinical research would use validated body-composition methods, record diet and activity, and analyse all assigned participants rather than only people who completed treatment successfully.
What would a first human study need to establish?
An initial Phase 1 study would normally start with a pharmaceutical-grade product and extensive preclinical toxicology. Researchers would collect blood and urine to measure the compound and its metabolites, while monitoring heart rhythm, blood pressure, neurological symptoms, liver and kidney tests and other safety measures.
Participants would not initially be expected to lose weight. The main questions would be whether exposure is predictable, whether NNMT-related biomarkers change and whether adverse effects limit further development.
Only after that foundation could a controlled obesity study test body weight, fat mass, metabolic health and durability. The present literature has not supplied this human development sequence.
Could long-term NNMT inhibition affect vitamin B3 biology?
Nicotinamide is both a vitamin-related nutrient and a metabolic signal. NNMT is one route by which cells process it. Blocking that route may leave more nicotinamide available for other pathways, but the body can also change production and removal elsewhere.
High nicotinamide availability is not automatically beneficial. NAD+ pathways, methyl donors and breakdown products are regulated together. Long-term inhibition could create adaptations that a short mouse study does not capture.
A human programme would need to measure nicotinamide, methylated metabolites, homocysteine and NAD-related compounds while looking for clinical effects. Homocysteine is an amino-acid-related blood compound influenced by methyl metabolism.
Why do cancer and obesity findings not combine into one benefit claim?
An NNMT inhibitor might be studied in fat cells because of energy metabolism and in tumour models because cancer cells alter metabolism. Those research aims involve different tissues, exposure and risks.
A compound that changes tumour-cell behaviour in a dish has not treated cancer. A compound that changes fat mass in mice has not treated obesity. Combining both sets of findings into a phrase such as “metabolic and anti-cancer benefits” creates a claim no study tested.
Cancer treatment development would also accept different risks from obesity treatment. A side effect that might be reasonable in life-threatening disease could be unacceptable in a long-term weight medicine.
Is 5-Amino-1MQ legal to sell as a supplement?
Calling a chemical a research compound does not make it an authorised food supplement or medicine. In January 2026, an FDA warning letter stated that 5-Amino-1MQ was not an eligible bulk substance for the section 503B outsourcing facility involved.
That finding concerned a specific US compounding route. It does not create a worldwide classification, but it directly contradicts claims that the compound is an established compounded medicine.
What information is missing from commercial product certificates?
A certificate of analysis may show identity and a chromatographic purity result. It may not report residual solvents, heavy metals, counter-ion content, water, microbial contamination or stability.
For a small molecule, crystal form and salt composition can affect how much active compound is present by mass. Without validated release specifications and batch traceability, two products carrying the same name may not be equivalent.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. It is a small quinolinium molecule. It is listed here because it is commonly sold beside peptides.
What does 5-Amino-1MQ inhibit?
It was designed to inhibit nicotinamide N-methyltransferase, or NNMT, an enzyme involved in nicotinamide and methyl-group metabolism.
Does 5-Amino-1MQ cause weight loss?
Mouse studies reported lower fat mass, but there is no established controlled human evidence showing safe or useful weight loss.
Has 5-Amino-1MQ been studied in humans?
No published controlled human treatment trial was identified for this review.
Is 5-Amino-1MQ FDA approved?
No. It is not an FDA-approved medicine for any condition.
Is 5-Amino-1MQ the same as NAD+?
No. NAD+ is a natural coenzyme. 5-Amino-1MQ is a synthetic NNMT inhibitor that may affect a pathway connected with nicotinamide metabolism.
Is an animal dose a human dose?
No. Animal exposures are study conditions. They cannot be converted into personal guidance without clinical development and safety evidence.
Is 5-Amino-1MQ safe?
Human safety has not been established. The absence of adequate human trials leaves both common and long-term risks uncertain.
Sources
Research reviewed through September 2026.